Tg Therapeutics, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2009 Dec2010 Dec2011 Mar2012 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.01M0.23M-0.63M-0.80M-0.78M-0.82M0.15M0.15M0.15M0.15M0.15M6.69M2.79M233.66M329.00M
Cost of Revenue 0.79M0.27M14.13M38.49M
Gross Profit -0.01M0.23M-0.63M-0.80M-0.78M-0.82M0.15M0.15M0.15M0.15M0.15M5.90M2.52M219.53M290.52M
Operating items
Amortization - Intangibles 0.15M0.15M
Research & Development 0.04M28.83M0.33M17.07M21.03M13.66M40.09M47.71M69.23M102.53M159.39M154.18M165.90M222.58M125.35M76.19M94.29M
Share-based Compensation (IS) 0.35M4.40M
Selling, General & Administrative 1.73M19.71M0.55M1.20M4.78M6.66M15.79M15.63M9.89M16.33M15.16M15.03M107.85M128.09M95.48M122.71M154.30M
Restructuring Costs 0.47M0.92M1.82M2.50M3.41M4.19M5.12M6.03M7.87M9.50M41.52M
Other Operating Expenses 14.35M-0.47M-0.92M-0.71M0.30M-3.41M-4.19M-5.12M-6.03M-7.87M-9.50M-41.52M0.79M0.27M14.13M38.49M
Operating Expenses 1.77M62.89M0.88M18.27M26.91M23.12M55.87M63.33M79.12M118.86M174.55M169.21M273.75M351.46M221.10M213.03M287.07M
Operating Income -1.77M-62.89M-0.88M-18.27M-26.90M-22.97M-55.72M-63.18M-78.97M-118.71M-174.40M-169.06M-273.59M-344.77M-218.32M20.63M41.93M
EBIT -1.77M-62.89M-0.88M-18.27M-26.90M-22.97M-55.72M-63.18M-78.97M-118.71M-174.40M-169.06M-273.59M-344.77M-218.32M20.63M41.93M
Non-operating items
Interest & Investment Income -0.59M-2.42M-0.00M0.02M0.03M0.06M0.17M0.32M0.29M0.86M
Other Non Operating Income -0.21M1.66M3.30M0.72M1.03M2.31M4.70M5.04M7.69M
Non Operating Income 1.02M-2.76M-0.01M0.02M1.04M2.49M-0.06M0.23M0.72M0.24M0.92M-3.82M-5.79M-3.33M-5.50M-7.57M-16.34M
Net income details
EBT -2.36M-65.31M-0.89M-18.04M-25.85M-20.48M-56.60M-63.98M-78.65M-119.26M-174.42M-174.34M-279.92M-348.10M-223.81M13.06M25.59M
Tax Provisions 0.33M0.39M2.21M
Profit After Tax -2.79M-60.13M-0.89M-18.29M-26.18M-20.48M-55.78M-62.95M-78.25M-118.48M-173.48M-172.87M-279.38M-348.10M-223.81M12.67M23.38M
Income from Non-Controlling Interests -0.04M-7.18M-8.11M
Income from Continuing Operations -2.36M-65.31M-0.89M-18.04M-26.18M-20.48M-56.60M-63.98M-78.65M-119.26M-174.42M-174.34M-279.92M-348.10M-223.81M12.67M23.38M
Consolidated Net Income -2.36M-65.31M-0.89M-18.04M-26.18M-20.48M-56.60M-63.98M-78.65M-119.26M-174.42M-174.34M-279.92M-348.10M-223.81M12.67M23.38M
Income towards Parent Company -2.36M-65.31M-0.89M-18.04M-26.18M-20.48M-56.60M-63.98M-78.65M-119.26M-174.42M-174.34M-279.92M-348.10M-223.81M12.67M23.38M
Net Income towards Common Stockholders -2.36M-65.31M-0.89M-18.04M-26.18M-20.48M-56.60M-63.98M-78.65M-119.26M-174.42M-174.34M-279.92M-348.10M-223.81M12.67M23.38M
Additional items
EPS (Basic) 0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M0.00M0.00M
EPS (Weighted Average and Diluted) 0.00M-0.00M-0.00M-0.00M0.00M0.00M
Shares Outstanding (Weighted Average) 0.04M0.04M0.13M5.06M25.06M33.50M43.96M52.52M54.73M70.65M82.90M99.56M131.49M142.94M145.34M151.41M155.67M
Shares Outstanding (Diluted Average) 115.33M132.22M135.41M
EBITDA -1.77M-62.89M-0.88M-18.27M-26.90M-22.97M-55.72M-63.18M-78.97M-118.71M-174.40M-169.06M-273.59M-344.77M-218.32M20.63M41.93M
Tax Rate 2.99%8.64%